Site icon 60 Minutes Tonight

Kratom: 60 Minutes Investigates the Billion-Dollar Industry Facing Addiction and Death Concerns

A booming billion-dollar industry selling kratom as a natural supplement is facing growing scrutiny over concerns about addiction, opioid-like effects and potentially deadly health consequences.

In a report titled “Kratom,” 60 Minutes correspondent Jon Wertheim investigates the controversial substance, which is widely available in gas stations, smoke shops and convenience stores across the United States despite longstanding warnings from federal health regulators.

Supporters promote kratom as a natural product that can boost energy, relieve discomfort and help people experiencing opioid withdrawal. However, medical experts have raised concerns about dependence, inconsistent product strength and serious adverse effects.

The investigation, featured in the November 15, 2026, edition of 60 Minutes, examines why kratom remains so accessible, the competing claims surrounding its benefits and the growing debate over how the industry should be regulated.

What Is Kratom and Why Has It Become So Popular?

Kratom comes from the leaves of Mitragyna speciosa, a tropical tree native to Southeast Asia, particularly Thailand, Indonesia and Malaysia.

The plant has traditionally been used for its stimulant and pain-relieving effects. In recent years, it has gained popularity in the United States, where it is sold in powders, capsules, drinks and concentrated extracts.

Kratom contains naturally occurring compounds, including mitragynine and 7-hydroxymitragynine, which interact with opioid receptors in the brain.

Its effects can vary depending on the dose, product formulation and individual user. Some people report increased alertness, while others experience sedation or pain relief.

The substance’s popularity has been driven partly by consumers seeking alternatives to prescription medications or conventional stimulants.

However, the fact that kratom comes from a plant does not automatically make it safe. Its active ingredients can produce significant physiological effects, particularly when consumed regularly or in concentrated forms.

Why Kratom Is Being Compared to Opioids

One of the biggest controversies surrounding kratom is its relationship with opioid drugs.

Although kratom is chemically different from traditional opioids such as morphine and oxycodone, some of its active compounds act on the same types of receptors.

This interaction helps explain why kratom can produce pain-relieving effects but also raises concerns about dependence and withdrawal.

People who use kratom frequently may develop tolerance, requiring larger amounts to achieve the same effects.

Some users experience withdrawal symptoms when they stop, including irritability, anxiety, sleep disturbances and physical discomfort.

The risks can differ substantially between traditional kratom leaf products and highly concentrated extracts, particularly products containing elevated levels of 7-hydroxymitragynine.

Health authorities have expressed particular concern about potent products that may expose consumers to much stronger opioid-like effects than they expect.

Wertheim’s investigation examines the growing debate over whether kratom should be marketed as a wellness supplement when its active compounds can produce opioid-related effects.

Can Kratom Help People Recover From Opioid Addiction?

Kratom advocates frequently argue that the substance can help people reduce or stop their use of more dangerous opioids.

Some consumers report using kratom to manage withdrawal symptoms or avoid returning to prescription painkillers and illicit opioids.

These personal accounts have helped fuel opposition to efforts to restrict or ban kratom products.

However, kratom has not been approved by the U.S. Food and Drug Administration as a treatment for opioid use disorder, and evidence supporting its effectiveness and safety remains insufficient.

Established medications such as buprenorphine and methadone have stronger clinical evidence demonstrating their effectiveness in treating opioid use disorder and reducing overdose risks.

Medical professionals are concerned that people relying on kratom without supervision may develop dependence or delay receiving proven treatment.

The debate presents a difficult regulatory question: how to address reports of perceived benefits while protecting consumers from products whose risks may not be fully understood.

FDA Warnings and Reports of Kratom-Related Deaths

The Food and Drug Administration has warned about kratom for more than a decade.

In 2012, the agency issued an import alert targeting certain kratom products entering the United States. It has subsequently raised concerns about addiction, serious adverse reactions and the absence of approved medical uses.

Reported health problems associated with kratom include nausea, seizures, liver injury and dependence.

Deaths have also been reported in association with kratom use, although some cases involve additional drugs or underlying medical conditions, making it important to distinguish association from proven causation.

Another concern is product quality. Without consistent manufacturing standards across the market, consumers may encounter products with differing concentrations, inaccurate labeling or contamination.

These issues become particularly significant when products are sold alongside ordinary consumer goods, potentially creating the impression that they have undergone the same safety evaluations as approved medicines.

Despite repeated regulatory warnings, kratom remains available through thousands of retail outlets across the country.

The Billion-Dollar Kratom Industry Faces Questions Over Regulation

Kratom has developed into a substantial commercial industry, with manufacturers and retailers offering an expanding range of products.

Its availability varies by state and locality, with some jurisdictions imposing restrictions or bans while others permit regulated sales.

This patchwork of rules has created an uneven market in which consumers may encounter different labeling requirements, product standards and restrictions depending on where they live.

The growth of concentrated extracts and products marketed for stronger effects has added further complexity to the debate.

Consumer advocates and health experts have called for clearer standards covering product composition, testing, labeling and marketing.

Industry supporters argue that responsible regulation would be preferable to prohibition, particularly for consumers who believe kratom has helped them.

Critics contend that existing oversight has not kept pace with the market’s expansion and the risks associated with certain products.

The 60 Minutes investigation examines these competing arguments while asking whether enough is being done to protect consumers.

Why the 60 Minutes Investigation Matters

The controversy surrounding kratom reflects a broader challenge in American public health: regulating products marketed as natural supplements when they contain powerful biologically active compounds.

For consumers, the distinction between traditional kratom leaf, concentrated extracts and enhanced 7-hydroxymitragynine products is particularly important.

These products should not automatically be treated as interchangeable because their strength, composition and risks can differ substantially.

The investigation also raises questions about how substances are advertised, whether consumers understand the potential for dependence and what responsibilities manufacturers and retailers have when selling them.

By examining both the experiences of kratom users and the concerns raised by regulators, Wertheim’s report explores why the substance has become one of the country’s most contentious supplement markets.

When to Watch Kratom on 60 Minutes

“Kratom” airs Sunday, November 15, 2026, as part of a new edition of 60 Minutes on CBS.

Correspondent Jon Wertheim investigates the billion-dollar kratom industry, its widespread availability and growing concerns about addiction, opioid-like effects and serious health risks.

Denise Schrier Cetta and Elizabeth Germino are the producers.

The episode airs 7:00–8:00 PM ET/PT on CBS and is available to stream on Paramount+.

The November 15 broadcast also features Norah O’Donnell’s investigation into a deadly Iranian drone strike that killed six American soldiers in Kuwait and Ariel Levy’s interview with actor John Malkovich.

The kratom report examines a central question facing consumers and regulators: how should a widely available plant-derived substance be controlled when supporters claim it offers benefits but health authorities continue to warn about potentially serious dangers?

More 60 Minutes November 15 2026

More Feature Articles 

Exit mobile version